Description of trials (same text as within vaccine strategies):

1. A phase I clinical trial conducted by Aviron (1999) demonstrated safety and immunogenicity for a subunit vaccine containing the gp220/350 surface glycoprotein.  The proprietary adjuvant was supplied by SmithKline Beecham.  The trial was a randomized, double-blind study, containing 67 healthy adult participants.  The study indicated that the vaccine was tolerated and safe.  Evidence of an immune response was shown by laboratory tests from participant sera (2).

2.The Queenland Institute of Medical Research has conducted a phase I trial designed to test the safety and immunogenicity of an Epstein-Barr virus cytotoxic T cell epitope vaccine.  The synthetic peptide, FLRGRAYGL (an HLA B8 restricted epitope from EBNA-3A), is in an emulsion of tetanus toxoid, water, and oil adjuvant Montanide ISA 720.  Healthy volunteers who are EBV negative and who are HLA B8 positive have shown no adverse reactions to date (7).

3. A phase I clinical trial of the recombinant vaccina virus mentioned above has been successful in China.  The trial was performed in three distinct human populations: EBV-positive adults exposed to the vaccina virus, EBV-positive children not exposed to the vaccina virus, and EBV-negative infants not exposed to the vaccina virus.  No significant antibody variations were observed in the adults but EBV-neutralizing titers increased in the vaccinated children, while antibodies to the viral capsid antigen remained the same.  All vaccinated infants developed MA antibodies with neutralizing properties in vitro (8).
 
 

[back to vaccines]